🇪🇺 Ly-Cov555 in European Union

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Ly-Cov555 (BAMLANIVIMAB) regulatory status in European Union.

Marketing authorisation

EMA

Application: EMEA/H/C/005836
Marketing authorisation holder: Eli Lilly Nederland B.V.
Local brand name: Bamlanivimab and etesevimab for COVID-19
Status: withdrawn

Read official source →

Other Infectious Disease approved in European Union

Frequently asked questions

Is Ly-Cov555 approved in European Union?

Yes. EMA has authorised it.

Who is the marketing authorisation holder for Ly-Cov555 in European Union?

Eli Lilly Nederland B.V. holds the EU marketing authorisation.